Everyone is going into the Coronavirus pool. I honestly wish we would quit going there and stay away from a Chinese partnership on that indication. If we have a Chinese co that wants to license for cancer and we can protect our patent, maybe, but I will pass on some short term hype that the rest of the pharma world is chasing.
On a related note, what would treating Coronavirus do to the pricing model? I understand that is probably a short term dosage, but it will look bad when we try to get $100k /yr for cancer patients.